Screener
Tarsus Pharmaceuticals, Inc. TARS Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 43,271,347 shares issued and outstanding at June 30, 2026 (unaudited); 42,553,931 shares issued and outstanding at December 31, 2025 | 6 | 6 |
| Additional paid-in capital | 799,429 | 769,667 |
| Accumulated other comprehensive income (loss) | (557) | 381 |
| Accumulated deficit | (452,146) | (426,628) |
| Total stockholders’ equity | 346,732 | 343,426 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s common stock?
- Tarsus Pharmaceuticals, Inc. (TARS) reported common stock of 200M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s common stock changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s common stock decreased by 0.0% year-over-year, from 200M to 200M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s common stock?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s common stock has grown at a 0.0% compound annual growth rate (CAGR), from 200M to 200M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Tarsus Pharmaceuticals, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude